Navigation Links
Idenix Pharmaceuticals Reports First Quarter Financial Results
Date:4/30/2009

Total operating expenses 17,326 23,844 ------ ------ Loss from operations (13,315) (21,800) Other income (expense), net (49) 939 ---- --- Loss before income taxes (13,364) (20,861) Income tax benefit 438 401 --- --- Net loss $(12,926) $(20,460) ========= ========= Basic and diluted net loss per share: ($0.23) ($0.36) ======= ======= Shares used in calculation of basic and diluted net loss per share: 56,940 56,274 ====== ====== (1) Stock-based compensation expenses included in operating expenses amounted to approximately: Research and development $439 $660 General and administrative 817 880

                     IDENIX PHARMACEUTICALS, INC.

                CONDENSED CONSOLIDATED BALANCE SHEETS

                          (IN THOUSANDS)

                            (UNAUDITED)

                                                      March 31, December 31,
                                                          2009       2008

    ASSETS
    Cash and cash equivalents                           $62,567    $41,509
    Marketable securities                                     -      1,424
    Receivables from related party                          81
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... and synthetic processes prefer to settle into equilibriuma ... is within the realm of non-equilibrium conditions where ... in energy and phases, such as temperature fluctuations, ... humans to regulate their body temperature, airplanes to ... activity. , But even though these conditions ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... balances – 4 steps – One Recommendation: the web-based ... narrows down the mass of product choices to a ... , First, select the working environment, then enter the ... define the accuracy – it’s really that simple. Specifying ... to models that fit best with the customer’s industry ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 As ... manage numerous projects in the MENA region during 2014 ... have a preferred provider agreement with DZS to manage ... MENA region,” said Global VP of R&D and President ... has developed excellent operational practices with a focus on ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... 2011 Palatin Technologies, Inc. (NYSE Amex: PTN ) ... of shares of its common stock and warrants to purchase common ... market conditions and there can be no assurance as to whether ... actual size or terms of the offering. Roth Capital ...
... GREAT NECK, N.Y., Feb. 23, 2011 Scarguard Labs, ... of scars, psoriasis and other dermatological problems through the ... delivery system, announced today that they have received approval ... consumers throughout Canada. "We are very pleased ...
... Quanterix Corporation, a single molecule diagnostics company providing ... in vitro diagnostics markets, today announced the online publication ... Si ngle Mo lecule A rray (SiMoA™) ... straightforward measurement.  The article appears in the journal ...
Cached Biology Technology:Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 3Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability 2
(Date:7/24/2014)... researchers and patients have hoped that embryonic stem cells ... bodycould provide insight into numerous diseases perhaps even be ... by the inability to transfer research and tools from ... because human ESCs are "primed" and slightly less plastic ... Powell, and Haoyi Wang, who are scientists in the ...
(Date:7/24/2014)... Africa in mid-July 2014, as the annual fire season ... areas of increased temperatures, are heavily sprinkled across the ... Congo (northeast), and Zambia (southeast). Thick gray smoke rises ... especially in the Democratic Republic of the Congo, strong ... fire season is an annual event in this region, ...
(Date:7/24/2014)... release is available in German . ... to recognize and respond to threats to health, and ... detailed understanding of the mechanism underlying immunologic memory, however, ... have converged to support the hypothesis that the persistence ... cells with stem-cell-like potential. Until now, there was no ...
Breaking Biology News(10 mins):Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3
... 2013 The Damon Runyon Cancer Research Foundation ... its spring 2013 Clinical Investigator Award Committee review. ... are outstanding early career physician-scientists conducting patient-oriented cancer ... of the nation,s leading scientists and clinicians. ...
... other conditions caused by malfunctions in the body,s nerve ... treat. The problem is that one medicine may help ... which drugs will work with individual patients may be ... seemingly identical neurons can behave the same even though ...
... discovered a mechanism that triggers chronic inflammation in ... today in Nature Immunology , suggest a ... the way to a new class of therapies ... diseases without crippling the immune system. Alzheimer,s, atherosclerosis ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 2Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 3Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 4Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 5Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 6Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 7Nerve cells can work in different ways with same result 2Researchers discover new way to block inflammation 2
... Intended Use: Vision Mount is formulated for covering tissue ... soluble OR alcohol insoluble end products. , ... ... chromogens such as Fast-Red or AEC that require an aqueous ...
... potent Rnase free Ribonuclease Inhibitor ... broad range of temperatures and ... not inhibit SP6, T7, or ... M-MLV reverse transcriptase or Taq ...
... kit, 110 to 220 V, enables ... doubles flow rates and valve capacity ... kit includes the Maximizer base unit, ... tubing kit, system cable 30, and ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: